Alector ALEC
Alector announces Q3 2026 financial results and business updates
Item 2.02 Reports results
- Form
- 8-K
- Filed
- Importance
- Major
- Accession
- 0001193125-26-449813
- $138.7 million in cash, cash equivalents, and investments as of September 30, 2026
- Received $100 million upfront payment from Genentech for AL050 license agreement
- AL137 targets first-in-human dosing in April 2027
- AL164 and AL062 target first-in-human studies in Q2 2028
Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.
The reading, claim by claim
- Under Item 2.02, the company said it announced its financial results for the quarter ended September 30, 2026, and that a press release with those results is attached as Exhibit 99.1.
- The filing states that the information furnished under Item 2.02 and Item 9.01, including Exhibit 99.1, is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934.
- It is also not incorporated by reference into other filings unless a specific reference says so.
- The report is signed by Arnon Rosenthal, Ph.D., Co-founder and Chief Executive Officer, and dated November 5, 2026.
4 of 4 claims matched the filing text.
For perspective, checked against its own source
From the 10-Q for the quarter ended September 30, 2026
- For context, in its 10-Q for the quarter ended September 30, 2026, Alector reported revenue of $162.9 million and net income of $124.6 million.
- That filing gives an operating margin of 76.0%, a net margin of 76.5%, and a revenue change from a year earlier of +4895.9%.
From the filing
Item 2.02 Results of Operations and Financial Condition.
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2026, Alector, Inc. (the "Company") announced its financial results for the quarter ended September 30, 2026.1 1A press release announcing these results, which is attached hereto as Exhibit 99.1, is incorporated herein by reference.1
All of the information furnished in Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended2, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such a filing.3
Item 9.01 Financial Statements and Exhibits.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
Description
99.1
Press Release dated November 5, 2026
104
Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ALECTOR, INC.
By:
Similar companies
Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.
- Protalix BioTherapeutics PLX public float $113M, Jun 30, 2025
- Fate Therapeutics FATE public float $113M, Jun 30, 2025
- Caribou Biosciences CRBU public float $113M, Jun 30, 2025
- Protara Therapeutics PRTO public float $112M, Jun 30, 2025
- TuHURA Biosciences HURA public float $111M, Jun 30, 2025